Nanosonics Limited

NAN.ASX

Health Care

The Company is focused on the research, development, and commercialisation of innovative technologies in infection control and decontamination. The Company's strategic goal is to establish itself as a recognised global leader in economical, safe, low or

Market Data

Price

$3.160

-0.0%

Market Cap

$944.3M

P/E Ratio

47.5x

EPS

$0.067

Div. Yield

0.00%

52-Week Change

-0.2%

Recent Announcements

1 Jun 2026 Sph Neutral

Ceasing to be a substantial holder

JPMorgan Chase & Co. and its affiliates ceased to be a substantial holder.

29 May 2026 Sph Neutral

Becoming a substantial holder

JPMorgan Chase & Co. and its affiliates became a substantial holder (5.04%).

28 May 2026 Sph Neutral

Ceasing to be a substantial holder

UBS Group AG ceased to be a substantial holder.

26 May 2026 Sph Neutral

Becoming a substantial holder

UBS Group AG became a substantial holder (5.12%).

13 May 2026 Sph Neutral

Ceasing to be a substantial holder

UBS Group AG ceased to be a substantial holder.

12 May 2026 Sph Neutral

Becoming a substantial holder

UBS Group AG became a substantial holder (5.29%).

11 May 2026 Sph Neutral

Ceasing to be a substantial holder

UBS Group AG ceased to be a substantial holder.

20 Apr 2026 Sph Neutral

Becoming a substantial holder

UBS Group AG became a substantial holder (5.34%).

17 Apr 2026 Sph Neutral

Ceasing to be a substantial holder

UBS Group AG ceased to be a substantial holder.

15 Apr 2026 Sph Neutral

Becoming a substantial holder

UBS Group AG became a substantial holder (5.69%).

Get real-time alerts for NAN

Receive AI-powered earnings summaries and instant notifications when Nanosonics Limited releases results.